Novartis Files Patent Infringement Lawsuit to Block Entresto Generics
In its latest effort to defend against forthcoming Entresto copycats, Novartis is taking to U.S. federal court to allege infringement against several generics players.
In a new lawsuit, Novartis sued Viatris subsidiary Mylan plus Alembic, Crystal Pharmaceutical, MSN Pharmaceuticals and Nanjing Noratech. Those companies are seeking FDA approval for their generic versions of blockbuster heart drug Entresto, but Novartis alleges infringement of its ‘918 patent, which is set to expire in November 2026.
Novartis claims it will be “irreparably damaged” by the generic companies’ attempts to win regulatory approvals for their products. The Swiss drugmaker asked the District Court of Delaware to halt potential approvals until no earlier than the Nov. 8, 2026, patent expiration.
